What is the mechanism of action of trimebutine?

Trimebutine Mechanism of Action

Trimebutine acts primarily as a non-selective agonist at peripheral mu, kappa, and delta opioid receptors, while also modulating gastrointestinal peptide release and functioning as a multiple-ion channel modulator in the gut. 1, 2

Primary Mechanisms

Opioid Receptor Activity

• Trimebutine and its N-desmethyl metabolite bind to all three major opioid receptor subtypes (mu, delta, and kappa) without true specificity for any single subtype 3
• The drug displays good affinity for these receptors in both brain and myenteric plexus preparations, with IC50 values ranging from 0.75 to 39 microM depending on the receptor subtype 3
• This opioid receptor activation mediates the gastrointestinal motility effects of the drug 2, 4

Gastrointestinal Peptide Modulation

• Trimebutine stimulates the release of motilin, which contributes to its prokinetic effects 2
• The drug modulates release of other peptides including vasoactive intestinal peptide (VIP), gastrin, and glucagon 2
• Clinical studies demonstrate that trimebutine significantly reduces VIP levels and increases neuropeptide Y (NPY) levels in patients with constipation-predominant IBS 5

Ion Channel Effects

• At higher concentrations, trimebutine attenuates colonic motility by inhibiting L-type calcium channels 6
• At lower concentrations, it depolarizes membrane potentials by reducing BK(ca) currents, resulting in enhanced muscle contractions 6
• This concentration-dependent dual effect explains its utility in both hypermotility and hypomotility disorders 1, 6

Functional Effects on the GI Tract

Motor Activity

• Gastric effects: Accelerates gastric emptying 1, 2
• Small intestine: Induces premature phase III of the migrating motor complex, with 100 mg IV reducing the MMC cycle from 86.4 minutes to 32.5 minutes 4
• Colon: Modulates contractile activity in a bidirectional manner depending on baseline motility state 1, 2

Visceral Sensitivity

• Trimebutine decreases reflexes induced by gut lumen distension in animal models, suggesting a role in modulating visceral hypersensitivity 2
• This visceral analgesic effect contributes to its efficacy in treating abdominal pain independent of its motor effects 1

Clinical Relevance

The naloxone-reversible effects of trimebutine confirm that its actions are mediated through opioid receptors, as demonstrated in human studies where naloxone 0.8 mg IV suppressed trimebutine's stimulatory action on intestinal motility 4. This multi-level mechanism—from motility regulation to pain control—distinguishes trimebutine from simple antispasmodics and explains its broad efficacy across different functional gastrointestinal disorders 1.